Abstract
No public abstract is available from the verified source records.
Suresh de Silva
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Antitumor necrosis factor-like ligand 1A therapy targets tissue inflammation and fibrosis pathways and reduces gut pathobionts in ulcerative colitis
10.1093/ibd/izab193 · 2022
Innate lymphoid cells activated by the cytokine TL1A link colitis to emergency granulopoiesis and the recruitment of tumor-promoting neutrophils
10.1016/j.immuni.2025.12.008 · 2026
Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a phase 2a single-arm study
10.1016/j.cgh.2021.06.011 · 2021
P633 first-in-human pharmacokinetic and safety study of an anti-TL1A antibody, TEV-48574, in healthy volunteers and asthma patients
10.1093/ecco-jcc/jjad212.0763 · 2024
TL1A drives TH1, TH2 and TH17 pathways in human lamina propria cells in IBD
10.1016/s0016-5085(26)03148-3 · 2026
No additional external references are available.